Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of Creatine Supplementation in Attenuating Chemotherapy-related Cognitive Decline in Patients With Early-stage Breast Cancer Undergoing Chemotherapy.

NCT07372144 is registered in ClinicalTrials.gov with D'Or Institute for Research and Education as lead sponsor.

NCT NCT07372144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07372144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of Creatine Supplementation in Attenuating Chemotherapy-related Cognitive Decline in Patients With Early-stage Breast Cancer Undergoing Chemotherapy.
Lead sponsor
D'Or Institute for Research and Education
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
June 1, 2028
Enrollment
227 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer